Clinical trial
Efficacy and Safety of Velcade Plus Dexamethasone (VD), VD+Cyclophosphamide or VD Plus Lenalidomide in MMY Patients Who Are Refractory or Have Relapsed After Their Primary Therapy for MMY and Have Achieved Stable Disease After 4 Cycles of VD
NCT00908232 is registered in ClinicalTrials.gov with Janssen-Cilag International NV as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of Velcade Plus Dexamethasone (VD), VD+Cyclophosphamide or VD Plus Lenalidomide in MMY Patients Who Are Refractory or Have Relapsed After Their Primary Therapy for MMY and Have Achieved Stable Disease After 4 Cycles of VD
- Lead sponsor
- Janssen-Cilag International NV
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 31, 2008
- Completion date
- August 31, 2011
- Enrollment
- 163 (actual)
- Sites
- 42
Conditions
As the registry lists them; a condition with its own page is linked.